US 6,310,185 B1Granted

Recombinant human anti-Lewis Y antibodies

AssigneeMemorial Sloan Kettering Cancer Center

InventorsThomas P. Wallace, Kathryn Lesley Armour, Francis Joseph Carr, Lloyd J. Old, Elisabeth Stockert, Sydney Welt, Kunio Kitamura, Pilar Garin-Chesa

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The invention provides for the production of several humanized murine antibodies specific for the antigen Lewis Y, which is recognized by murine atibodies specific for the Lewis Y antigen. The Lewis Y antigen is expressed in normal tissues but the level of expression is higher in certain tumour types so that the antigen can be used as a marker for cells of some breast, colon, gastric, esophageal, pancreatic, duodenal, lung, bladder and renal carcinomas and gastric and islet cell neuroendocrine tumours. The invention also provides for numerous polynucleotide encoding humanized Lewis Y specific antibodies, expression vectors for producing humanized Lewis Y specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis Y specific antibodies. Additionally, the invention provides methods of treating cancer using humanized Lewis Y specific antibodies.

Claims6

Dependent claims

A humanized antibody that specifically binds to the Lewis Y antigen, comprising a humanized variable region wherein a heavy chain variable region is selected from the group consisting of 3S193HuVH (SEQ ID NO:

22), 3S 193 HuVHT (SEQ ID NO:
23) in which the framework region of the heavy chain variable region comprises an amino acid substitution of threonine at position 24, 3S193 HuVHA (SEQ ID NO:
24) in which the framework region of the heavy chain variable region comprises an amino acid substitution of alanine at position 74, 3S193 HuVHAS (SEQ ID NO:
25) in which the framework region of the heavy chain variable region comprises an amino acid substitution of serine at position 76 and 3S193 HuVHASY (SEQ ID NO:
26) in which the framework region of the heavy chain variable region comprises an amino acid substitution of tyrosine at position 79, and a light chain variable region is selected from the group consisting of 3S193 HuVK (SEQ ID NO:
28) and 3S193 HuVKF (SEQ ID NO:
33) in which the framework region of the light chain variable region comprises an amino acid substitution of phenylalanine at position 71.

4 more elements

Dependencies are inferred from the claim text.